Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 16/20 | 0.71 |
| ▸ | SELL | P14151 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.36 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.36 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26407401 | 1.00 | SELE (0.71) | SELESELLMAPK1LGALS8LGALS3 | |
| SCHEMBL22247269 | 1.00 | SELE (0.71) | SELESELLMAPK1LGALS8LGALS3 | |
| SCHEMBL22400259 | 1.00 | SELE (0.71) | SELESELLMAPK1LGALS8LGALS3 | |
| SCHEMBL17151748 | 0.94 | SELE (0.74) | SELESELLMAPK1LGALS8LGALS3 | |
| SCHEMBL19939764 | 0.94 | SELE (0.74) | SELESELLMAPK1LGALS8LGALS3 | |
| SCHEMBL16659822 | 0.94 | SELE (0.74) | SELESELLMAPK1LGALS8LGALS3 | |
| SCHEMBL17148785 | 0.94 | SELE (0.74) | SELESELLMAPK1LGALS8LGALS3 | |
| SCHEMBL23026833 | 0.93 | SELE (0.73) | SELESELLMAPK1 | |
| SCHEMBL22006661 | 0.93 | SELE (0.73) | SELESELLMAPK1 | |
| SCHEMBL22898057 | 0.93 | SELE (0.73) | SELESELLMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165882-A1 | COMPOUNDS AND METHODS FOR REDUCTION OF CANCER CELL BURDEN AND PROTECTION OF NORMAL HEMATOPOIESIS | GLYCOMIMETICS, INC. (US) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165882-A1 | COMPOUNDS AND METHODS FOR REDUCTION OF CANCER CELL BURDEN AND PROTECTION OF NORMAL HEMATOPOIESIS | FLT3, SELE, SELL | SELE 2/4885SELL 3/4885MAPK1 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.